DISCLAIMER: This note is intended for US recipients only and, in particular, is not directed at, nor intended to be relied upon by any UK recipients. Any information or analysis in this note is not an offer to sell or the solicitation of an offer to buy any securities. Nothing in this note is intended to be investment advice and nor should it be relied upon to make investment decisions. Read our full disclaimer, here.

Burning Down the COVID Infrastructure

By Nathan Brinkman

In Q1, BioNTech made its most decisive break from its COVID-era identity. Its starting to execute a controlled demolition of its pandemic-era cost structure and rebuilding as a focused oncology company. BNTX's posted revenue of $136 million came in 31% below the prior-year quarter and missed analyst consensus by roughly 30%, somewhat expected given the seasonal trough of COVID vaccine demand. Operating loss widened to $783 million as R&D spending for the oncology pipeline continued to climb. But the real news arrived alongside the financials: 1,860 manufacturing jobs cut, four sites closed across Germany and Singapore, $584 million in targeted annual savings by 2029, a $1 billion share buyback announced, full-year guidance reaffirmed, and five new Phase 3 trials initiated for pumitamig in a single quarter. The thesis still remains in tact. The risks, however, have not diminished. The founder succession, the Arbutus litigation clock, and the 2026 pipeline readouts remain binary events that will define the stock’s trajectory through year-end.